Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients
Published Online: Thursday, January 16, 2014
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
Study finds higher risk of cardiovascular and cerebrovascular disease in COPD patients, suggests spread of inflammation may be a factor.
Hospitalization rates for chronic obstructive pulmonary disease were found to be lower in communities that have smoke-free policies.